GTEC Enters Global Cannabis Market with Export Agreement to Israel
09 3월 2021 - 9:39AM
GTEC Holdings Ltd. (TSXV:GTEC) (OTCQB: GGTTF) (FRA: 1BUP)
(“
GTEC”, the “
Company” or
“GTEC Cannabis
Co.”) a multi-licensed producer of handcrafted, high quality
cannabis, is pleased to announce the signing of an export deal
pertaining to the Israeli medical cannabis market (the
“
Agreement”).
- Executes multi-year agreement to export a minimum of 500 KG
annually to Israel, one of the world’s largest import markets for
medical cannabis
- Agreement enables GTEC to enter into global distribution of its
handcrafted ultra-premium flower
- Export deal demonstrates the demand for GTEC products within
Canada and globally
The Company has entered into an agreement with Focus Medical
Herbs Ltd. ("Focus Medical"), an Israeli medical cannabis
company with which IM Cannabis Corp. (“IMC”) (NASDAQ: IMCC)
has exclusive distribution agreements to export cannabis from
Canada to Israel, subject to meeting all regulatory requirements
both in Israel and Canada. Under the terms of this agreement,
GTEC is expected to become a key supplier of cannabis to Focus
Medical. The Company’s initial shipments of cannabis will be
produced by its wholly-owned subsidiary, Grey Bruce Farms
(“GBF”), located in Tiverton, Ontario, with the expectation
that GTEC will export 500 to 1,000 KG per year.Michael Blady,
Co-founder and VP of GTEC commented, "We are very excited to sign
this agreement adding our ultra-premium product to the well-known
IMC brand in Israel, this demonstrates the robust demand for GTEC
products within Canada and globally. With the signing of this deal,
GTEC will become an up-and-coming player within the global cannabis
market, while continuing to drive significant incremental revenues
and gross margin.”“Medical cannabis patients in Israel are starting
to demand more imported indoor products from Canada. By partnering
with GTEC to supply high-THC flower from its Canadian indoor
facility, IMC is leveraging this increasing demand from patients
and will, for the first time, bring into Israel a truly
ultra-premium quality product. We are thrilled about the launch of
this new category and expect to grow its market share
domestically,” Oren Shuster, Chief Executive Officer of IMC
commented.In order to qualify as a supplier to the Israeli medical
cannabis market, GBF successfully completed a rigorous audit
process conducted by The Institute of Quality & Control
(“IQC), the largest private certification body in
Israel. This comprehensive audit process covered all aspects
of the GBF operations, including cultivation, quality assurance and
human resources. As a result, GBF has received its ICANN-G.A.P
(Good Agricultural Practices) accreditation from IQC.The Company
considers the Agreement to reinforce GTEC's competitive advantage
in the production of ultra-premium cannabis. Currently there are
more than 320 Standard Cultivation Licences issued by Health
Canada, and being selected as Focus Medical's key supplier
demonstrates the quality and demand of GTEC's products. The Company
will continue to evaluate opportunities within the global cannabis
market, with the objective to further expand its global
distribution channels.About IM Cannabis Corp.IMC is a
multi-country operator (MCO) in the medical cannabis sector
headquartered in Israel and with operations In Israel and Germany.
Over the past decade, the IMC brand has become synonymous with
quality and consistency in the Israeli medical cannabis market. IMC
has also expanded its business to offer intellectual
property-related services to the medical cannabis industry.In
Europe, IMC operates through Adjupharm, a German-based subsidiary
and EU-GMP certified medical cannabis distributor. IMC’s European
presence is augmented by strategic alliances with various
pan-European EU-GMP cultivators and distributors to capitalize on
the increased demand for medical cannabis products in Europe and
bring the IMC brand and its product portfolio to European
patients.About Focus Medical Herbs Ltd. Focus Medical is one
of eight original licensed producers of medical cannabis in Israel
and has over 10 years of experience growing high-quality medical
cannabis in the Israeli market. Focus Medical is an “investee” of
IMC under IFRS due to the IMC’s “de facto control” over Focus
Medical, despite not having any direct or indirect ownership of it.
Focus Medical has an exclusive commercial agreement with IMC to
distribute its production under the IMC brand. In addition to its
own capacity, Focus Medical has signed supply agreements with other
cultivators for additional supply using its proprietary genetics
and for sale under the IMC brand.For parties interested in
global export opportunities, please contact:Michael
Blady - Co-Founder and Vice President
mb@gtec.co604-720-3474Non-Brokered Private PlacementThe
Company is also pleased to announce that it has completed its
previously announced non-brokered private placement (the
“Offering”) of 13,750,000 units (each, a “Unit”) at a
price $0.20 per Unit for gross proceeds of $2,750,000. Each
“Unit” issued in the placement consists of one common share and one
half of one share purchase warrant entitling the holder to purchase
one additional share at $0.30 for a period of three years from
closing of the Offering.The Company filed for price reservation
based on the closing price per common share of $0.245 on February
5, 2021 (which was the 52-week high for the Common Shares as of
February 5, 2021). Commitments to subscribe in the Offering that
were received on or before the close of markets on February 9,
2021, totaled $2.75 million. Further commitments were later
received with demand significantly exceeding the $4 million,
however as a result of the increase in the Company’s share price,
the Company elected to close the book and not accept any further
commitments. All securities issued pursuant to the Offering are
subject to a statutory hold period lasting four months and one day
following the closing of the Offering.About GTEC Cannabis
CoGTEC Cannabis Co. cultivates, markets and distributes premium
cannabis products. The Company has four operational facilities
licensed by Health Canada and currently distributes cannabis
through medical and recreational sales channels. GTEC’s
recreational product portfolio is crafted from unique cultivars and
marketed under its BLK MKT™ , Tenzo™, Cognōscente™ and
Treehugger™ brands. The Company’s medical cannabis brand,
GreenTec™, is distributed nationally to qualified patients through
its through its GreenTec Medical web-site and various licensed
partners.GTEC is a publicly traded corporation, listed on the TSX
Venture Exchange (GTEC), OTCQB Venture Market (GGTTF) and Frankfurt
Stock Exchange (1BUP). The Company’s headquarters is located in
Kelowna, B.C. and it has operations in the Canadian provinces of
British Columbia, Alberta and Ontario.To learn more about the
Company or to access the most recent Corporate Presentation, please
visit our website at www.gtec.coNeither the TSX Venture
Exchange nor its Regulation Services Provider (as that term is
defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this
release.CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING
INFORMATION:This news release includes certain “forward-looking
statements” and “forward-looking information” under applicable
Canadian securities legislation (collectively, “forward -looking
statements”). Forward-looking statements predict or describe
our future operations, business plans, business and investment
strategies and the performance of our investments. These
forward-looking statements are generally identified by their use of
such terms and phrases as “intend,” “goal,” “strategy,” “estimate,”
“expect,” “project,” “projections,” “forecasts,” “plans,” “seeks,”
“anticipates,” “potential,” “proposed,” “will,” “should,” “could,”
“would,” “may,” “likely,” “designed to,” “foreseeable future,”
“believe,” “scheduled” and other similar expressions. The
forward-looking statements contained herein may include, but are
not limited to, GTEC becoming a key supplier of cannabis to Focus
Medical, the expectation that GTEC will export 500 to 1,000 KG of
cannabis per year to Focus Medical, GTEC becoming an up-and-coming
player within the global cannabis market, while continuing to drive
significant incremental revenues and gross margin, and the
Agreement reinforcing GTEC's competitive advantage in the
production of ultra-premium cannabis. Forward-looking statements
are necessarily based upon a number of estimates and assumptions
that, while considered reasonable, are subject to known and unknown
risks, uncertainties, and other factors which may cause the actual
results and future events to differ materially from those expressed
or implied by such forward-looking statements. Such factors
include, but are not limited to: general business, economic,
competitive, political and social uncertainties; delay or failure
to receive board, shareholder or regulatory approvals, where
applicable and the state of the capital markets. There can be no
assurance that such statements will prove to be accurate, as actual
results and future events could differ materially from those
anticipated in such statements. For instance and among other
things, there are risks that the COVID-19 pandemic may disrupt the
Company’s operations, those of the Company’s suppliers and
distribution channels and negatively impact the use of the
Company’s products, the Company may not be able to successfully
ship to Israel and generate positive gross margins; issues
compliance with applicable environmental, economic, health and
safety, energy and other policies and regulations with respect to
the use of cannabis; actions of third parties such as competitors,
activist investors or federal, provincial, territorial or local
regulatory authorities, self-regulatory organizations, plaintiffs
in litigation or persons threatening litigation; changes in
regulatory requirements in relation to the Company’s business and
products. Accordingly, readers should not place undue reliance on
forward-looking statements, which speak only as of the date of this
news release. The Company disclaims any intention or obligation to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise, except as
required by law.
For additional information, please contact:
GTEC Cannabis Co.
1-800-351-6358
contact@gtec.co
GTEC (TSXV:GTEC)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
GTEC (TSXV:GTEC)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024